Business Wire

Global Life Sciences Survey Reveals Significant Improvements in Inspection Readiness Among CROs

Del

Veeva Systems (NYSE:VEEV) today unveiled the results of the Veeva 2016 Paperless TMF Survey: CRO Report. The global industry survey of trial master file (TMF) owners shows growing use of electronic trial master file (eTMF) solutions among clinical research organizations (CROs) as a result of benefits in audit and inspection readiness. In addition, findings reveal that CROs are leading the drive toward active TMF management and making strides in the use of performance metrics and data to improve the efficiency and speed of clinical trials.

eTMF Solutions Significantly Improve Inspection Readiness

eTMFs are helping CROs to maintain complete and accessible trial master files to reduce the number of inspection findings. CROs who use eTMF applications are achieving significant improvements across major inspection finding categories such as fewer duplicate documents (61%), misfiled documents (53%), and incomplete documents (51%).

Given these benefits, one of the top drivers of eTMF adoption among a majority of CROs (65%) is improved audit and inspection readiness. At the same time, CROs are now less reliant on document exchange methods that are more difficult to track and provide little to no audit trail. For example, the use of email for document exchange is down significantly from 80% in 2014 to 61% today, while almost a third (31%) are using an eTMF application to share TMF documents with sponsors (up from 24% in 2014).

CROs Leading Transition to Active TMF Management

With a focus on improving inspection readiness, CROs are shifting to an active TMF management approach, a trend that has increased since the first Veeva Paperless TMF Survey in 2014. In active TMF management, purpose-built eTMF applications manage documents and processes in real-time as the TMF is being generated and provide global access for stakeholders. Conversely, in passive TMF management, TMF documents are simply stored and archived in file systems and other static repositories at the end of a trial rather than as part of the trial workflow.

Nearly one-third of CROs (30%) now use purpose-built eTMF applications that enable active TMF management, up from 21% in 2014. At the same time, there was a significant drop in the use of passive eTMF systems, including cloud file shares (9% in 2016 vs. 21% in 2014) and local file systems (16% in 2016 vs. 26% in 2014). In addition, CROs have significantly reduced the amount of TMF documents managed on paper, with less than a quarter (22%) reporting that most to all TMF documents are managed on paper (down from 47% in 2014).

eTMFs Provide Better Visibility into TMF Performance

Another key driver of eTMF adoption among a majority of CROs (57%) is improved visibility into performance metrics. CROs are not only capturing metrics but also making large strides in putting the data to use, with a quarter of CROs (24%) now extensively using TMF data to improve trial processes (up from 16% in 2015) and another 46% leveraging data in some cases (up from 40% in 2015).

In terms of other key benefits of eTMF adoption, 44% of CROs find that they have better visibility into performance metrics. In addition, a majority of CROs have achieved significant improvements in central and remote auditing (56%) and automated tracking and reporting of documents (56%), both of which are key in providing timely and accurate status updates to sponsors.

“Over the past several years CROs have played a pivotal role in moving the life sciences industry toward more efficient clinical trial processes,” said Jill Johnston, vice president of Veeva Vault Clinical. “As clinical trials become increasingly outsourced, we’ll see that trend continue especially as demand grows for unifying systems, processes, and stakeholders across clinical operations.”

To hear the full results of the Veeva 2016 Paperless TMF Survey: CRO Report, see Veeva’s presentation at the Outsourcing in Clinical Trials New England conference on September 7 at 3:15 p.m. Conference attendees can also visit Veeva booth #7 for a copy or download it here.

Survey Methods

The Veeva 2016 Paperless TMF Survey: CRO Report consisted of 13 questions, many of which included sub-questions with response matrices. Survey questions were designed for individuals with knowledge of TMF document processes and with partial or full responsibility for a TMF within their organization. The survey was commissioned by Veeva Systems and conducted by Fierce Markets. Completion of the survey was voluntary, and a $5 donation was made to Doctors Without Borders for each valid completion of the full survey. All respondents were offered a summary of the survey results. No other compensation was offered or provided.

Additional Information

For more on Veeva Vault eTMF, please visit: veeva.com/eu/etmf

Stay updated on the latest Veeva news on LinkedIn: linkedin.com/company/veeva-systems

Follow @Veeva_EU on Twitter: twitter.com/veeva_eu

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 450 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s filing on Form 10-Q for the period ended April 30, 2016. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

Contact information

Veeva Systems Inc.
Sue Glanville
sue@catalystcomms.co.uk
+44 (0) 7715 817589
or
Cate Bonthuys
cate@catalystcomms.co.uk
+44 (0) 7746 546773

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Exclusive Group Adds Mellanox to BigTec Portfolio19.10.2017 08:00Pressemelding

Exclusive Group, the value-added services and technologies (VAST) group, today announced it has struck a major distribution agreement with Mellanox Technologies to add the market-leading vendor’s datacentre interconnect solutions to the global BigTec portfolio. The deal, which sees Mellanox and BigTec team up in 24 countries across EMEA and APAC, brings global expansion opportunities to both parties as well as hundreds of reseller partners, providing the ideal complement to storage and hyper-converged solutions from fellow BigTec vendors including Nutanix and Rubrik. “Mellanox has a unique and comprehensive technology offering that reflects both its commitment to open standards in networking and cloud computing, and its hunger to continually disrupt the datacentre market,” said Martin Bichler, Group Vendor Manager, BigTec. “This is yet another bonus for BigTec specialist resellers and

More Firms Select Duco for Mandatory MiFID II Reconciliation19.10.2017 07:01Pressemelding

Duco, the global provider of self-service data normalization and reconciliation services, today announced that a further three firms will be using Duco Cube, the company’s flagship reconciliation solution, for MiFID II reporting reconciliation. The firms include Redburn, Europe’s largest independent equities broker, and two global banks. Ranith de Silva, Operations Manager at Redburn, said: “MiFID II transaction data needs to undergo a number of enrichment processes between front office capture and the final report, which need to be replicated in the reconciliation process, covering large complex data sets. The quick deployment, flexibility and usability of Duco's self-service application enables us to efficiently build towards this reconciliation process with very little technical support.” Regular reconciliation is a mandatory requirement under MiFID II. The firms w

SIAE MICROELETTRONICA Successfully Tests The SDN Application iVeritas in Telefónica Deutschland’s SDN Live Wireless Network19.10.2017 07:00Pressemelding

SIAE MICROELETTRONICA announces the successful deployment of iVeritas in Telefónica Deutschland's mobile backhaul as part of the TST project. Telefónica Deutschland Transport SDN Trial (TST), is a project whose long-term aim is offering value added services on future 5G network infrastructure in an SDN environment. As part of this project SIAE MICROELETTRONICA, a Telefónica long term supplier of wireless technology, deployed its new SDN application named iVeritas offering multivendor performance analytics and preventive maintenance analysis. iVeritas sits on top of the OpenDaylight transport SDN controller that through an SDN mediator interfaces to existing SNMP microwave links, the selected portion of the network was composed by links from three different vendors. iVeritas collected performance information from the links, correlating the data and presenting them acco

Rimini Street Expands Investment and Operations in Europe18.10.2017 22:00Pressemelding

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy18.10.2017 21:43Pressemelding

Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which

IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 20:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom